Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ZGNX
Zogenix, Inc.
stock NASDAQ

Inactive
Mar 4, 2022
26.68USD+1.599%(+0.42)11,252,392
Pre-market
0.00USD-100.000%(-26.26)0
After-hours
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 23, 2022
11:03AM EST  The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More   Benzinga
Jan 20, 2022
01:21AM EST  & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zogenix, Inc. - ZGNX   PR Newswire
Jan 19, 2022
02:43PM EST  Needham Downgrades Zogenix to Hold   Benzinga
02:38PM EST  Mid-Afternoon Market Update: Dow Tumbles 150 Points; Yumanity Therapeutics Shares Plunge   Benzinga
12:26PM EST  Mid-Day Market Update: US Stocks Turn Negative; Zogenix Shares Spike Higher   Benzinga
10:32AM EST  The law firm of Wohl & Fruchter LLP is investigating whether the directors of Zogenix, Inc. (Nasdaq: ZGNX) (Zogenix) acted in the best interests of ZGNX shareholders in approving the proposed acquisition of Zogenix by UCB, a global biopharmaceutical company.   GlobeNewswire Inc
10:27AM EST  Mid-Morning Market Update: Markets Rise; Bank of America Posts Upbeat Profit   Benzinga
10:09AM EST  Shares of Zogenix, Inc. (ZGNX) are surging nearly 70% on Wednesday morning on the news that it has agreed to be acquired by Belgian-based UCB SA for $1.9 billion.   RTTNews
05:02AM EST  UCB Announced it Will Acquire Zogenix for $26/Share in Cash   Benzinga
01:04AM EST  UCB To Acquire Zogenix For Up To US$1.9 Bln Or EUR 1.7 Bln   RTTNews
01:00AM EST  UCB to acquire Zogenix   PR Newswire
Dec 21, 2021
08:05AM EST  Zogenix Submits New Drug Application For FINTEPLA In Japan For The Treatment Of Epileptic Seizures Associated With Dravet Syndrome   Benzinga
08:00AM EST  Zogenix Submits New Drug Application for FINTEPLA   GlobeNewswire Inc
Dec 20, 2021
08:06AM EST  Zogenix Submits Type II Variation Application To The European Medicines Agency To Expand The Use Of FINTEPLA For The Treatment Of Seizures Associated With Lennox-Gastaut Syndrome   Benzinga
08:00AM EST  Zogenix Submits Type II Variation Application to the European   GlobeNewswire Inc
04:56AM EST  SVB Leerink Maintains Outperform on Zogenix, Lowers Price Target to $32   Benzinga
Dec 16, 2021
04:05PM EST  Zogenix Reports Granting of Inducement Awards   GlobeNewswire Inc
Dec 2, 2021
04:28PM EST  Zogenix To Present New FINTEPLA Data At AES 2021 Dec. 3-7   Benzinga
04:17PM EST  Zogenix To Present New FINTEPLA (fenfluramine) Data at   GlobeNewswire Inc
Dec 1, 2021
08:04AM EST  Zogenix Announces FDA Acceptance For Priority Review Of Supplemental New Drug Application For FINTEPLA For Treatment Of Seizures Associated With Lennox-Gastaut Syndrome   Benzinga
08:00AM EST  Zogenix Announces U.S. FDA Acceptance for Priority Review of   GlobeNewswire Inc
Nov 17, 2021
04:05PM EST  Zogenix Reports Granting of Inducement Awards   GlobeNewswire Inc
Nov 11, 2021
04:05PM EST  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that members of its management team will participate infireside chats at two upcoming investor conferences: the Stifel 2021 Virtual Healthcare Conference and Guggenheim Virtual 3rd Annual Neuro/Immunology Conference.   GlobeNewswire Inc
Nov 5, 2021
09:31AM EDT  Recap: Zogenix Q3 Earnings   Benzinga
09:26AM EDT  Zogenix Q3 EPS $(1.04) Misses $(0.97) Estimate, Sales $22.60M Beat $22.33M Estimate   Benzinga
Nov 4, 2021
08:19AM EDT  The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO   Benzinga
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Nov 3, 2021
11:06AM EDT  Zogenix Earnings Preview   Benzinga
Nov 1, 2021
08:00AM EDT  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will host a key opinion leader (KOL) webinar on thymidine kinase 2 deficiency (TK2d) and MT-1621 on Monday, November 8, 2021, at 12:00 PM Eastern Time.   GlobeNewswire Inc
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 21, 2021
08:00AM EDT  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced data that it will report its financial results for the third quarter ended September 30, 2021 and host a corporate update conference call and webcast after the market close on Thursday, November 4, 2021, at 4:30 PM Eastern Time.   GlobeNewswire Inc
Oct 19, 2021
08:00AM EDT  Zogenix Reports Granting of Inducement Awards   GlobeNewswire Inc
Oct 1, 2021
09:31AM EDT  Zogenix Sponsored Study Titled 'A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder' Posted To ClinicalTrials.gov, Study Not Yet Recruiting   Benzinga
Sep 30, 2021
03:06PM EDT  Zogenix's Fintepla Shows Long-Term Seizure Frequency Reductions In Childhood Epilepsy   Benzinga
08:07AM EDT  Zogenix Announces New FINTEPLA Data Show Long-Term Seizure Frequency Reductions In Patients With Lennox-Gastaut Syndrome; Co. Reports 'Median reduction in drop seizure frequency was 39.4% at 3 months and 51.8% for patients assessed over 10-12 months'   Benzinga
08:00AM EDT  -- Median reduction in drop seizure frequency was 39.4% at 3 months (n= 227; p<0.0001) and 51.8% for patients assessed over months 10 to 12 (n=170; p<0.0001). -- A Supplemental New Drug Application (sNDA) was recently submitted seeking FDA approval for the use of FINTEPLA in LGS.   GlobeNewswire Inc
Sep 28, 2021
08:19AM EDT  Zogenix Submits SNDA For FINTEPLA For Seizures Associated With Lennox-Gastaut Syndrome   RTTNews
08:02AM EDT  Zogenix Reports Submission Of Supplemental New Drug Application For FINTEPLA For Treatment Of Seizures Associated With Lennox-Gastaut Syndrome   Benzinga
08:00AM EDT  -- Supplemental New Drug Application (sNDA) submission is supported by existing clinical data, including positive data from Companys Phase 3 trial, Study 1601, in which the primary endpoint was met with high statistical significance. -- Lennox-Gastaut Syndrome (LGS) is estimated to affect approximately 30,000-50,000 patients in the U.S.   GlobeNewswire Inc
Sep 16, 2021
05:39PM EDT  Zogenix Reports Granting of Inducement Awards   GlobeNewswire Inc
Sep 9, 2021
11:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021   Benzinga
08:11AM EDT  UBS Initiates Coverage On Zogenix with Buy Rating, Announces Price Target of $23   Benzinga
Aug 30, 2021
12:33PM EDT  University Of Oxford-Sponsored Study Titled 'Fenfluramine and Cognition (FEN&Cognition)' Posted To ClinicalTrials.Gov; Study Is Recruiting   Benzinga
11:09AM EDT  Return on Capital Employed Insights for Zogenix   Benzinga
Aug 26, 2021
08:34AM EDT  Zogenix Receives Orphan Drug Designation For FINTEPLA In Japan   RTTNews
08:00AM EDT  Zogenix Receives Orphan Drug Designation for FINTEPLA   GlobeNewswire Inc
Aug 16, 2021
05:02PM EDT  Zogenix Reports Granting of Inducement Awards   GlobeNewswire Inc
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 6, 2021
06:17AM EDT  Needham Maintains Buy on Zogenix, Lowers Price Target to $44   Benzinga
04:35AM EDT  SVB Leerink Maintains Outperform on Zogenix, Lowers Price Target to $37   Benzinga
Aug 5, 2021
05:25PM EDT  Recap: Zogenix Q2 Earnings   Benzinga
04:35PM EDT  Zogenix Q2 EPS $(1.05) Misses $(0.94) Estimate, Sales $18.79M Beat $17.08M Estimate   Benzinga
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 3, 2021
04:05PM EDT  Zogenix(NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced thatStephenJ. Farr, Ph.D., President and Chief Executive Officer, andMichael Smith, Chief Financial Officer, will participate in a virtual fireside chat onTuesday, August 10, 2021, at theBofA SMID Cap 2H21 Ideas Conference.   GlobeNewswire Inc
Jul 22, 2021
08:00AM EDT  Zogenix(NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that it will report its financial results for the second quarter ended June 30, 2021 and host a corporate update conference call and webcast after the market close on Thursday, August 5, 2021, at 4:30 PM Eastern Time.   GlobeNewswire Inc
Jul 21, 2021
08:07AM EDT  Zogenix Highlights Recognition Of FINTEPLA In Epilepsy & Behavior Editorial   Benzinga
08:00AM EDT  -- In Epilepsy & Behavior editorial, authors write that FINTEPLA data demonstrate unprecedented level of seizure control for treated patients living with Dravet syndrome, a severe, debilitating childhood-onset epilepsy. -- Authors also recognize FINTEPLA for achieving clinically important results in caregiver-reported outcomes such as patient and family quality of life.   GlobeNewswire Inc
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jun 21, 2021
08:00AM EDT  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced thatmembers of its management team will participate in two upcoming investor conferences: the Raymond James Human Health Innovation Conference and SVB Leerink CNS Forum.   GlobeNewswire Inc
May 11, 2021
04:01PM EDT  Zogenix to Participate in the BofA Securities 2021 Healthcare   GlobeNewswire Inc
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
05:24PM EDT  Recap: Zogenix Q1 Earnings   Benzinga
04:40PM EDT  Zogenix Q1 EPS $(1.00) Beats $(1.02) Estimate, Sales $13.70M Beat $12.33M Estimate   Benzinga
04:01PM EDT  -- Continued positive momentum for U.S.launch of FINTEPLA(fenfluramine) oral solution in Dravet syndrome, with total net product sales of$12.3 millionand total revenue of $13.7 million in the first quarter, representing quarter-over-quarter increases of 53% and 61%, respectively   GlobeNewswire Inc
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
Apr 27, 2021
08:00AM EDT  -- FINTEPLA is approved in the U.S. and European Union as an add-on therapy for the treatment of seizures associated with Dravet syndrome in patients aged two years and older. -- The new program supports physician access to FINTEPLA in other parts of the world, where local regulations allow, including European countries where reimbursement has not yet been established.   GlobeNewswire Inc
Apr 22, 2021
10:51AM EDT  Zogenix's Fintepla Associated With Improvements in Seizure Control, Executive Functions In Childhood Epilepsy Disorder   Benzinga
08:01AM EDT  Zogenix Presents New Data at Virtual AAN 2021 Showing Improved   GlobeNewswire Inc
08:00AM EDT  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the first quarter ended March 31, 2021 and host a corporate update conference call and webcast after the market close on Thursday, May 6, 2021, at 4:30 PM Eastern Time.   GlobeNewswire Inc
Apr 16, 2021
08:03AM EDT  Zogenix Presents New Data From A Study Highlighting Impact Of Treatment With FINTEPLA (Fenfluramine) Oral Solution On Dravet Syndrome Patients, Caregivers, And Families At Virtual AAN 2021   Benzinga
08:00AM EDT  Zogenix Presents New Data from a Study Highlighting the Impact of   GlobeNewswire Inc
Apr 8, 2021
08:00AM EDT  Zogenix to Participate in the 20th Annual Needham Virtual   GlobeNewswire Inc
Mar 25, 2021
08:00AM EDT  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will participate in a fireside chat on Wednesday, March 31, 2021, at the Stifel 3rd Annual CNS Day.   GlobeNewswire Inc
Mar 16, 2021
05:48AM EDT  Zogenix Awarded U.S. Patent 10,950,331 'Control system for control of distribution of medication'   Benzinga
Mar 2, 2021
08:00AM EST  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Michael Smith, Executive Vice President, Chief Financial Officer, and Treasurer, will present a corporate overview and participate in a fireside chat on Wednesday, March 3, 2021, at the Raymond James Institutional Investors Conference.   GlobeNewswire Inc
Feb 25, 2021
04:25PM EST  Zogenix Q4 EPS $(1.26) Misses $(1.00) Estimate, Sales $8.50M Beat $7.29M Estimate   Benzinga
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
04:03AM EST  Earnings Scheduled For February 25, 2021   Benzinga
Feb 18, 2021
08:00AM EST  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Friday, February 26, 2021, at the 10th Annual SVB Leerink Global Healthcare Conference.   GlobeNewswire Inc
Feb 11, 2021
08:00AM EST  Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2020 and host a corporate update conference call and webcast after the market close, on Thursday, February 25, 2021, at 4:30 PM Eastern Time.   GlobeNewswire Inc
Feb 3, 2021
09:07AM EST  Zogenix Shares Up 21% In Sympathy Following Jazz Pharma/GW Pharma Deal; Mizuho Says Deal Has 'Positive Read Through' To Zogenix; Firm Maintains Buy Rating, $55 Price Target On Zogenix   Benzinga
Feb 1, 2021
03:00AM EST  Zogenixs FINTEPLA (Fenfluramine)   GlobeNewswire Inc
Jan 11, 2021
08:06AM EST  Zogenix Sees Q4 2020 Sales ~$8.1M Vs $4.08M-$10.3M Est.   Benzinga
08:00AM EST  Zogenix Announces Preliminary, Unaudited Fourth Quarter 2020 Net   GlobeNewswire Inc
Dec 21, 2020
08:03AM EST  The European Commission Approves Zogenix's FINTEPLA Oral Solution for the Treatment of Seizures in Dravet Syndrome   Benzinga
08:00AM EST  The European Commission Approves Zogenixs   GlobeNewswire Inc
Dec 3, 2020
05:45PM EST  Tevard Biosciences, Zogenix Announce Collaboration To Advance Novel Gene Therapies For Dravet Syndrome And Other Genetic Epilepsies   Benzinga
05:43PM EST  Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene   PR Newswire
Dec 1, 2020
08:00AM EST  -- New long-term safety, efficacy, and durability data for FINTEPLA (fenfluramine) oral solution in Dravet syndrome -- Full results from Phase 3 study of FINTEPLA in Lennox-Gastaut syndrome -- New data from investigator-initiated study in CDKL5 Deficiency Disorder   GlobeNewswire Inc
Nov 11, 2020
08:00AM EST  Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, CFO, and Treasurer, will participate in a fireside chat on Wednesday, November 18, 2020, at the Stifel 2020 Virtual Healthcare Conference.   GlobeNewswire Inc
Nov 10, 2020
08:40AM EST  The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies   Benzinga
Nov 9, 2020
04:03PM EST  Zogenix Q3 EPS $(1.08) Misses $(0.98) Estimate, Sales $2.86M Beat $2.51M Estimate   Benzinga
04:01PM EST  Zogenix Provides Corporate Update and Reports Third Quarter 2020   GlobeNewswire Inc
04:13AM EST  Earnings Scheduled For November 9, 2020   Benzinga
Nov 8, 2020
03:58PM EST  The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions   Benzinga
12:47PM EST  The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs   Benzinga
Oct 29, 2020
08:23AM EDT  Zogenix Announces Date Change For Third Quarter 2020 Financial Results And Conference Call And Webcast To November 9   Benzinga
08:00AM EDT  Zogenix Announces Date Change for Third Quarter 2020 Financial   GlobeNewswire Inc
Oct 26, 2020
08:01AM EDT  Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and nine months ended September 30, 2020 and host a corporate update conference call and webcast after the market close on Tuesday, November 10, 2020, at 4:30 PM Eastern Time.   GlobeNewswire Inc
Oct 16, 2020
08:05AM EDT  Zogenix Receives Positive CHMP Opinion For FINTEPLA Oral Solution For Treatment Of Seizures In Patients With Dravet Syndrome   Benzinga
08:00AM EDT  Zogenix Receives Positive CHMP Opinion for FINTEPLA   GlobeNewswire Inc
Oct 15, 2020
05:52PM EDT  After Market Hours: Flexible Solutions, Zogenix, PQ Group   RTTNews
05:26PM EDT  10 Stocks Moving In Thursday's After-Hours Session   Benzinga
04:18PM EDT  Zogenix Reports Will Present New Data For FINTEPLA In Dravet Syndrome At Child Neurology Congress   Benzinga
04:17PM EDT  -- Interim data from open-label extension trial showedsubstantial seizure reductions were maintainedin patients treated with FINTEPLA for up to two years   GlobeNewswire Inc
Oct 5, 2020
04:03PM EDT  Zogenix, Inc. Announces Closing of Exercise by Initial Purchasers   GlobeNewswire Inc
Oct 2, 2020
08:00AM EDT  Zogenix Presents New Data at the World Muscle Society Conference 2020   GlobeNewswire Inc
Sep 23, 2020
11:28PM EDT  Zogenix Prices Offering Of $200 Mln Aggregate Principal Amount Of 2.75% Convertible Senior Notes Due 2027   RTTNews
11:00PM EDT  Zogenix, Inc. Prices $200.0 Million Convertible Senior Notes Offering   GlobeNewswire Inc
09:52AM EDT  Shares of Zogenix Inc. (ZGNX) are falling more than 15 percent or $3.40 in Wednesday's morning trade at $19.18.   RTTNews
Sep 22, 2020
04:14PM EDT  Zogenix, Inc. Announces Proposed Convertible Senior Notes Offering   GlobeNewswire Inc
Sep 21, 2020
08:05PM EDT  Correction: In this updated news release issued September 21, 2020 by Zogenix, Inc, the name of the organization, WorldWideWomen, has been corrected. The full corrected press release follows.   GlobeNewswire Inc
08:19AM EDT  Zogenix Appoints Caroline Loewy, Mary Stutts And Denelle Waynick To Newly Created Seats On Board   RTTNews
08:01AM EDT  Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced the appointments of Caroline M. Loewy, Mary E. Stutts and Denelle J. Waynick to newly created seats on its Board of Directors, effective immediately. Zogenixs Board now includes 10 members, nine of whom are independent.   GlobeNewswire Inc
Sep 10, 2020
08:02AM EDT  Zogenix Announces Top-Line Results From Third Pivotal Phase 3 Trial Of FINTEPLA In Dravet Syndrome; Says 'Results corroborate highly statistically significant convulsive seizure reductions seen in earlier multinational Phase 3 studies of FINTEPLA'   Benzinga
08:00AM EDT  -- Results corroborate highly statistically significant convulsive seizure reductions seen in earlier multinational Phase 3 studies of FINTEPLA in Dravet syndrome   GlobeNewswire Inc
Aug 25, 2020
09:35AM EDT  Benzinga's Top Upgrades, Downgrades For August 25, 2020   Benzinga
06:17AM EDT  Raymond James Initiates Coverage On Zogenix with Market Perform Rating   Benzinga
Aug 5, 2020
04:06PM EDT  Zogenix Q2 EPS $(0.96) Beats $(1.00) Estimate, Sales $1.03M Down From $1.07M YoY   Benzinga
04:01PM EDT  -- FINTEPLA (fenfluramine) in Dravet syndrome is now FDA approved and commercially launched in the U.S. -- More than 230 prescribers have already completed FINTEPLA REMS enrollment and certification -- FDA meeting scheduled in September to discuss planned sNDA for FINTEPLA in Lennox-Gastaut syndrome -- Held productive meetings with FDA to discuss MT1621 development program   GlobeNewswire Inc
04:21AM EDT  Earnings Scheduled For August 5, 2020   Benzinga
Jul 29, 2020
08:00AM EDT  Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2020, after the market close, and will host a corporate update conference call and webcast on Wednesday, August 5, 2020, at 4:30 PM Eastern Time.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC